We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications.
- Authors
Al-Nesf, Maryam A. Y.; Abdesselem, Houari B.; Bensmail, Ilham; Ibrahim, Shahd; Saeed, Walaa A. H.; Mohammed, Sara S. I.; Razok, Almurtada; Alhussain, Hashim; Aly, Reham M. A.; Al Maslamani, Muna; Ouararhni, Khalid; Khatib, Mohamad Y.; Hssain, Ali Ait; Omrani, Ali S.; Al-Kaabi, Saad; Al Khal, Abdullatif; Al-Thani, Asmaa A.; Samsam, Waseem; Farooq, Abdulaziz; Al-Suwaidi, Jassim
- Abstract
COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients. Prognostic markers for patients with COVID-19 are of critical importance in determining the course of SARS-CoV-2 infection and patient handling. Here the authors determine and apply a prognostic proteomic panel for risk and drug prediction in the management of SARS-CoV-2 infected patients.
- Subjects
COVID-19; PROGNOSTIC tests; PROGNOSIS; BLOOD proteins; DRUGS
- Publication
Nature Communications, 2022, Vol 13, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-022-28639-4